Company intelligence / Profile preview

Qi Biotechnology

Suzhou/Jiangsu region, Jiangsu, Chinaen.gzailiqi.com ↗

Ownership: Private
Development stage: Other

Overview

Qi Biodesign has developed advanced genome-editing tools enabling multiplex gene editing, fine-tuning of gene expression, and high-throughput trait discovery. The company has achieved regulatory milestones with biosafety certificates for two gene-edited plants—high oleic acid soybean and powdery mildew-resistant wheat—and secured a USDA exemption for its soybean product. Clinical results per se do not apply as this is an ag-biotech firm.

Modalities: Genome editing technologyRNA-guided nucleaseBase editorPrime editor
Industry: Agriculture & AgTech

Partnerships

MGI/BGI Group – partnership to introduce DNBSEQ-G99 sequencer/nanopore sequencer with MGI.

Beyond the preview

Go deeper on Qi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qi Biotechnology.

Explore the full profile